• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Innovation in Drug Delivery: The Future of Nanotechnology and Non-invasive Protein Delivery Product Image

Innovation in Drug Delivery: The Future of Nanotechnology and Non-invasive Protein Delivery

  • ID: 362978
  • November 2006
  • 137 Pages
  • Scripp Business Insights

FEATURED COMPANIES

  • Abraxis BioScience
  • Altea Therapeutics
  • ALZA Corporation
  • Elan
  • Emisphere
  • Flamel Technologies
  • MORE

"Drug delivery is one of the most dynamic and fast growing sectors of the pharmaceutical industry. The high level of innovation in this sector is evolving at a fast pace with products such as Pfizer’s inhaled insulin, Exubera, gaining US approval in January 2006.

‘Innovation in Drug Delivery’ provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set to revolutionize the market, such as products using ALZA Corporation’s E-TRANS and Altea’s PassPort patch transdermal technologies. This report will enable you to evaluate key marketed drugs, including Emend and Megace, and gain an insight into novel pipeline products to anticipate upcoming product launches and position yourself for success.

Use this report to understand how nanotechnology and other key technologies are changing drug delivery and how these can be implemented into your R&D process. Assess the impact of innovation in therapy areas including oncology, diabetes and infectious diseases and identify future opportunities for market growth.

Some key findings from this report...
- Solubility is a key resistor to drug delivery READ MORE >

FEATURED COMPANIES

  • Abraxis BioScience
  • Altea Therapeutics
  • ALZA Corporation
  • Elan
  • Emisphere
  • Flamel Technologies
  • MORE

Executive Summary 10

Introduction 10
Advances in nanotechnology 11
Targeted therapies in oncology 12
Innovation in pulmonary delivery 13
Innovation in transdermal delivery 14
Innovation in medical devices: stents and implants 15
Competitive landscape 16
The future of drug delivery 17

Chapter 1 Introduction 20
Summary 20
Introduction 21
Key indications 21
Key trends 22
Cost and revenue implications of innovative technology 23
Drivers of innovation 24
Poor patient compliance and injectable protein delivery 24
Needle-free injections 24
Non-invasive protein delivery 25
Poor solubility 25
Formulation technologies for poorly soluble compounds 26
Reducing drug dosage frequency 26
Combination products 26
Controlled release 27
Conclusions and key findings 28

Chapter 2 Advances in nanotechnology 32
Summary 32
Introduction 33
Advantages of nanotechnology for drug delivery 33
Marketed products using nanotechnology 35
Abraxane 35
Doxil 36
Potential for nanotechnology in drug delivery 37
Injectable delivery 38
Implantable delivery systems 38
Oral delivery 39
Transdermal delivery 39
Competitive landscape 40
Elan 40
Flamel Technologies 41
Michigan Nanotechnology Institute for Medicine and Biological Sciences 42
Abraxis BioScience 43
Others 43
The future of nanotechnology in drug delivery 44
Delivering cancer stem cell therapies 44
siRNA and gene therapy 45
Conclusions and key findings 45

Chapter 3 Targeted therapies in oncology 48
Summary 48
Introduction 49
Targeted therapies overview 49
Nanotechnologies to target cancers 50
Stealth 51
Transdrug 52
NanoCrystal 52
Monoclonal antibodies 53
Pipeline mAbs 54
Antibody fragments 56
PEGylation 56
UniBody technology 57
Inhaled monoclonal antibodies 57
Oral monoclonal antibodies 58
Drug delivery to brain tumors 58
Stem cell therapy 59
Synthetic toxins 59
Viral delivery systems 59
RNAi in chemotherapy 60
Conclusions and key findings 62

Chapter 4 Innovation in pulmonary delivery 64
Summary 64
Introduction 65
Advantages and disadvantages of pulmonary delivery 65
Advantages 66
Disadvantages 66
Key pulmonary delivery pipeline 67
Key indications for pulmonary drug delivery 68
Asthma and COPD 68
Diabetes 69
Inhaled insulin pipeline 70
CNS disorders 73
Infectious diseases 74
Other indications 76
Conclusions and key findings 77

Chapter 5 Innovation in transdermal delivery 80
Summary 80
Introduction 81
Transdermal drug delivery pipeline 81
Transdermal patch technologies 83
Passive patch 84
Noven Pharmaceuticals 85
Iomai 85
Active patches 85
ZARS Pharma 85
ALZA Corporation 86
Altea Therapeutics 87
TransPharma Medical 88
Future of transdermal drug delivery 89
Conclusion and key findings 89

Chapter 6 Innovation in medical devices:
stents and implants 92
Summary 92
Introduction 93
Implants 93
Injectable solid implants 93
Injectable microparticles 95
Drug-eluting stents 96
Marketed stents 96
Cypher 96
Taxus 97
Xience 97
Clinical trials 98
Cost effectiveness 99
Adverse events 99
Drug-eluting stent pipeline 100
ZoMaxx 100
Endeavor 101
Next generation drug-eluting stents 101
Controlled-release implantable microchips 102
MEMS technologies 103
Conclusions and key findings 103

Chapter 7 Competitive landscape 106
Summary 106
Introduction 107
Leading innovative drug delivery companies 107
Altea Therapeutics 109
Pipeline 109
Strategic and growth analysis 110
ALZA Corporation 110
Pipeline 111
Strategic and growth analysis 112
Elan 113
Pipeline 114
Strategic and growth analysis 114
Emisphere 116
Pipeline 116
Strategic and growth analysis 117
Nektar 118
Pipeline 118
Strategic and growth analysis 119
Key M&A and licensing activity 120
Drug delivery business strategy 120
M&A activity in drug delivery 121

Chapter 8 The future of drug delivery 124
Summary 124
Introduction 125
Nanotechnology 126
siRNA 127
Stem cells 128
Transmucosal drug delivery 129
Conclusions and key findings 131
Chapter 9 Appendix 134
IMS data 134
Bibliography 134
Index 136

List of Figures
Figure 1.1: Drivers of innovation in drug delivery 24
Figure 2.2: Sales of Abraxane, Taxol and generic paclitaxol in the US and 5EU, 2005-6 36
Figure 2.3: Doxil structure 37
Figure 3.4: Targeted oncology pipeline by indication, 2006 50
Figure 3.5: Sales of marketed oncology mAbs, 2004-5 54
Figure 4.6: Inhaled insulin market forecast, 2006-2015 70
Figure 4.7: Aradigm pain management AERx device 74
Figure 4.8: Sales forecasts of MedImmunes FluMist and CAIV-T in the US, 2004-2011 76
Figure 5.9: Transdermal drug delivery pipeline by therapy area, 2006 82
Figure 5.10: ALZA’s E-TRANS delivery system 87
Figure 6.11: Biophan’s nanomagnetic particle-based technology 95
Figure 7.12: Capabilities of leading innovative drug delivery companies, 2006 108
Figure 7.13: Licensing and collaboration strategy of leading innovative drug delivery companies
121

List of Tables
Table 1.1: Key companies specializing in long-acting injection technology 27
Table 2.2: Nanoparticles as drug delivery carriers 34
Table 2.3: Sales of cancer nanomedicine marketed products in the US and 5EU, 2005-6 35
Table 2.4: Key nanotechnology/nanomedicine deals, 2005-2006 38
Table 2.5: Sales of marketed products using Elan’s NanoCrystal technology in the US and 5EU,
2005-6 40
Table 2.6: Flamel’s product pipeline using the Medusa platform, 2006 42
Table 3.7: Key pipeline oncology drugs using nanotechnology, 2006 51
Table 3.8: Late stage oncology monoclonal antibody pipeline, 2006 55
Table 3.9: Antibody fragment pipeline, 2006 56
Table 3.10: Chemotherapeutic siRNA targets 61
Table 4.11: Key pulmonary/inhalable delivery pipeline, 2006 67
Table 4.12: Key pulmonary insulin pipeline, 2006 71
Table 5.13: Key late-stage transdermal patches, 2006 83
Table 5.14: Transdermal patch technology companies, 2006 84
Table 6.15: Key clinical trial with drug-eluting stents, 2006 98
Table 6.16: Comparison of costs for bare-metal and drug-eluting coronary stents, 2004 99
Table 6.17: Drug eluting stent pipeline, 2006 100
Table 7.18: Altea Therapeutic’s pipeline, 2006 109
Table 7.19: ALZA’s core technologies, 2006 111
Table 7.20: ALZA Therapeutics’ pipeline, 2006 111
Table 7.21: ALZA’s drug delivery deals, 2005-6 112
Table 7.22: Elan’s R&D pipeline, 2006 114
Table 7.23: Elan’s drug delivery deals, 2005-6 115
Table 7.24: Emisphere’s pipeline, 2006 117
Table 7.25: Emisphere’s drug delivery deals, 2005-6 117
Table 7.26: Nektar’s key innovative pipeline products, 2006 119
Table 7.27: Nektar Therapeutics’ drug delivery deals, 2005-6 119
Table 7.28: Drug discovery and technology deals made by the top 20 pharmaceutical companies,
2000–04 120
Table 7.29: Key drug delivery M&A activity, 2006 122

Altea Therapeutics
ALZA Corporation
Elan
Abraxis BioScience
Michigan Nanotechnology Institute for Medicine and Biological Sciences
Emisphere
Nektar
TransPharma Medical
Flamel Technologies
ZARS Pharma

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos